-+ 0.00%
-+ 0.00%
-+ 0.00%
Evotec, Bristol Myers Squibb Protein Degradation Partnership Receives Second FDA Investigational New Drug Acceptance For CELMoD Candidate, Phase 1 Expected In 2027
Share
Listen to the news
  • FDA clearance expands partnered molecular glue pipeline
  • Achievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high unmet need
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending